Cantaloupe Announces First Seed Software Expansion in Europe
Cantaloupe, Inc. (NASDAQ: CTLP), a digital payments and software services company that provides end-to-end technology solutions for self-service commerce, is excited to announce a partnership expansion that extends its footprint in Europe. In collaboration with Sweden-based HGM Dryckservice AB (HGM), Cantaloupe’s Seed software platform will be rolled out to support HGM’s growing micro markets business.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230504005514/en/
Cantaloupe, Inc. (NASDAQ: CTLP), a digital payments and software services company that provides end-to-end technology solutions for self-service commerce, is excited to announce a partnership expansion that extends its footprint in Europe with Sweden-based HGM Dryckservice AB (HGM). HGM will use Cantaloupe’s Seed software platform, which will be rolled out to support HGM’s growing micro markets business. (Photo: Business Wire)
“We are really excited to work with Cantaloupe and take advantage of the Seed platform through its Seed Markets solution,” said Peter Has, CEO of HGM. “The efficiencies that Seed Markets can deliver will improve our operational processes and will help us realize our accelerated growth plans.”
HGM was already a customer of Three Square Market (32M), a recent Cantaloupe acquisition. Because of the existing integration between 32M’s kiosk technology and the Seed platform, HGM can quickly transition onto Seed Markets within 30 days. Once fully trained, HGM’s team will be able to monitor and manage service schedules, pre-picking, warehouse inventory, reporting, and overall driver processes effectively and efficiently – all in one platform.
“We have 3 decades of experience helping operators drive revenue and decrease operational costs,” said Ravi Venkatesan, CEO of Cantaloupe, Inc. “That industry expertise and our quick implementation process were significant factors in HGM’s decision to go with Cantaloupe. Fully managing their micro market business in Seed Markets will be a huge advantage for them and a great win for us as we expand our services throughout Europe.”
Cantaloupe’s European-based team will be responsible for supporting local customers in the implementation of the Seed platform, which includes Seed Pro, Seed Office and Seed Markets. The team will provide both on-site and virtual training to ensure that operators and their teams are fully equipped to leverage Seed across their operations.
“We’ve seen the power of Seed in North America, with its ability to enable operators to streamline their business within one platform,” said Ravi Venkatesan. “Now, as we’ve stated in our strategic vision of international expansion, European operators are also able to capitalize on the benefits of Seed’s mobile and web-based tools to automate the thousands of decisions they make on a daily basis.”
To learn more about Cantaloupe, Inc., its vending management software and micro market technology, visit atcantaloupe.com.
About Cantaloupe, Inc.
Cantaloupe, Inc. is a software and payments company that provides end-to-end technology solutions for self-service commerce. Cantaloupe is transforming the self-service industry by offering one integrated solution for payments processing, logistics, and back-office management. The company’s enterprise-wide platform is designed to increase consumer engagement and sales revenue through digital payments, digital advertising, and customer loyalty programs, while providing retailers with control and visibility over their operations and inventory. As a result, customers ranging from vending machine companies to operators of micro markets, car charging stations, laundromats, metered parking terminals, kiosks, amusements, and more can run their businesses more proactively, predictably, and competitively. To learn more about Cantaloupe, Inc., visit cantaloupe.com, explore the Cantaloupe Blog, listen to the podcast UR Tech Insiders, or follow via LinkedIn, Twitter, Facebook, Instagram or YouTube.
About HGM Dryckservice AB
HGM Dryckservice AB provides food and coffee at work. With a wide selection of micro market and vending options, HGM Dryckservice, along with its suppliers, develops machines for every need. From coffee machines to vending all the way to food stores at work (Food Corner by HGM), HGM offers opportunities to rent, lease or purchase machines depending on specific needs. Serving restaurants, cafes and hotels, HGM aims to provide good and fast service for its customers and also offers technical service for the machines, as well as refill services and cleaning options. To learn more about HGM Dryckservice, visit hgmdryckservice.se or on Facebook and Instagram @hgmdryckservice.
G-CTLP
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230504005514/en/
Contact information
Jenifer Howard | 202-273-4246
jhoward@jhowardpr.com
media@cantaloupe.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom